Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Definitive diagnosis of CF based on the following:~   * One clinical feature consistent with CF and~  * Either a genotype with 2 identifiable mutations known to cause CF or a sweat chloride concentration \>60 mEq/L by pilocarpine iontophoresis~2. Pancreatic insufficiency documented by a monoclonal faecal elastase (FE) 100 μg/g stool at screening (test results within the previous 12 months are acceptable)~3. Currently receiving pancreatic enzyme replacement therapy~4. Adequate nutritional status based on the following: body mass index (BMI) \>19 kg/m2 in adult subjects or a BMI percentile 10th percentile for age in adolescent (12 to 17 years age group) subjects~5. Are clinically stable with no evidence of concomitant illness or acute upper or lower respiratory tract infection that requires antibiotics during the 7-day interval prior to screening and preceding entry into this clinical study~Exclusion Criteria:~1. Age \<12 years~2. Known contraindication, hypersensitivity, or intolerance to pork or other porcine PEPs~3. Current uncontrolled diabetes mellitus~4. History of solid organ transplantation~5. History of surgery affecting the bowel function and weight gain

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EUR-1008 then Kreon (Type: EXPERIMENTAL): * EUR-1008 during Treatment Period 1 (29 days ±2 days) and~* Kreon during Treatment Period 2 (29 days ±2 days).
- Kreon then EUR-1008 (Type: EXPERIMENTAL): * Kreon during Treatment Period 1 (29 days ±2 days) and~* EUR-1008 during Treatment Period 2 (29 days ±2 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).